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radial distances were compared to those of the clinically 
used contours (inter-observer) and the average contours per 
patient and observer (intra-observer). The registration 
process was initiated with the localization of gold fiducial 
markers (FMs) and, if necessary, adjusted manually for 
rotation and/or translation. Prostate V100 and D90 were 
determined for each contour and registration. The two 
dosimetric parameters (DPs) were scaled with the patients 
clinical DPs (inter, see Figure 1) or the patients average per 
observer (intra) to remove the natural variation in DPs 
between patients. 
Results: Prostate contours on US resulted in an inter-observer 
variability of 1.1 mm (1 SD with respect to the clinical 
contours) and an intra-observer variability of 0.6 mm (1 SD 
with respect to the average contour per patient and 
observer). US-contouring alone led to dosimetric differences 
of 1.6% of the clinical V100 and 9.3% of the clinical D90, and 
an intra-observer variability of 0.6% (V100) and 1.0% (D90). 
US-CBCT registrations varied within 2.0% of the clinical V100 
and 3.1% of the clinical D90. For MRI-CBCT registration, this 
was 1.3% and 2.1% respectively. The intra-observer 
variabilities of US-CBCT (V100: 0.9% and D90: 1.5%) and MRI-
CBCT (V100: 0.7% and D90: 1.0%) registration were smaller 
than the inter-observer variabilities. During registration, 
observers found 91% of the FMs on US, 100% on CBCT and 99% 
on MRI. 78% of the US-CBCT registrations were manually 
adjusted based on the urethra contours and iodine seeds. 




Conclusions: US- and MRI-CBCT registrations showed little 
variability compared to the inter-observer variability in US-
contouring. Inter-observer contouring caused D90 variations 
of 9.3% from the clinical value. The intra-observer contouring 
variability was comparable to the registration variability. 
Good FM visibility on MRI scans resulted in small registration 
variabilities. The inferior FM visibility on US was compensated 
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Purpose/Objective: Evaluation of tolerance, early and late 
toxicity of HDR brachytherapy combined with interstitial 
hyperthermia (IHT) in patients treated for prostate cancer. 
Materials and Methods: 105 patients were treated for 
prostate cancer using HDRBT combined with IHT. 79 patients 
were treated fo primary prostate adenocarcinoma, and 26 
patients for local recurrence after previous definitive EBRT. 
The treatment of 76 patients consisted of external beam 
radiotherapy (EBRT) to the total dose of 50 Gy and HDRBT 
boost (21Gy in 2 fractions), 3 patients received HDRBT as a 
monotherapy to the total dose of 45 Gy in 3 fractions. 
Salvage HDRBT for local cancer recurrence was performed to 
the total dose of 30 Gy in 3 fractions. IHT was planned before 
each HDRBT fraction to the temperature of 40-43ºC for 60 
minutes. Toxicity was assessed according to Common Toxicity 
Criteria for Adverse Events version 4.03. 
Results: The median follow-up time was 26.4 months (range 
7 – 61 months). We didn't observe any grade 3 or higher 
gastrointestinal (GI) or genitourinary (GU) early toxicities. 
Early GU grade 1 and 2 toxicities were common, but only two 
patients (1,9%) experienced acute urethral stenosis and 
required temporary catheterisation (grade 2). Only two 
patients (1,9%) developed late grade 3 urinary tract 
obstruction with urinary retention, which required 
transurethral resection of the prostate (TURP). The incidence 
of grade 2 toxicity in this group of patients did not exceed 
30%. There were no late grade 2 or higher complications from 
the gastrointestinal tract. There were no statistically 
significant differences in early complications between the 
groups of patients treated with radical and salvage intent, 
except for haematuria (p <0.01) and rectal bleeding (p 
<0.01). 
Conclusions:The combination of HDRBT with IHT is well 
tolerated. The profile of early and late complications is 
acceptable, while the incidence of grade 3 toxicity remained 
within a few percent only. 
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Purpose/Objective: High Dose-Rate brachytherapy (HDRB) 
for the treatment of prostate cancer provides biochemical 
control comparable to other treatment modalities with the 
benefit of reducing dose to the OARs. Generally delivered in 
conjunction with external beam radiotherapy HDRB has the 
potential advantage of allowing dose escalation due to the 
high dose delivered during the treatment fraction. However, 
the wide ranges of fractionation regimes used in different 
centres make it difficult to establish clear guidelines for 
